Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report
- PMID: 26917690
- PMCID: PMC4801313
- DOI: 10.1073/pnas.1522052113
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Comment on
-
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8. Proc Natl Acad Sci U S A. 2015. PMID: 26372962 Free PMC article.
References
-
- Shen L, Ji HF. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(26):2537. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources